The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?
about
Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes.Conclusions: Calls to action for improving the life of MS patients and their families.Introduction: Do we need multi-stakeholder colloquia in MS?The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?
P2860
The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The regulator's perspective: H ...... cally evaluated in the future?
@en
type
label
The regulator's perspective: H ...... cally evaluated in the future?
@en
prefLabel
The regulator's perspective: H ...... cally evaluated in the future?
@en
P2093
P2860
P50
P356
P1476
The regulator's perspective: H ...... cally evaluated in the future?
@en
P2093
Bianca Meesen
Daan Ja Crommelin
Jean-Louis Prugnaud
Karl Broich
P2860
P356
10.1177/1352458516650744
P433
P577
2016-08-01T00:00:00Z